Skip to content

Clinical trials

Phase 2 Diabetes Mellitus, Type 1 trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Phase: Phase 2 Country / region: United States Clear all

178 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20007
20012
20025
20033
20043
20054
20068
20076
200812
20096
20109
20114
201210
20137
20146
201511
20166
20176
20181
201912
20207
20217
20225
202311
20242
20255
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed110
Terminated25
Recruiting17
Active, not recruiting13
Not yet recruiting6
Withdrawn5
Unknown status2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)19
National Institute of Allergy and Infectious Diseases (NIAID)10
Massachusetts General Hospital6
Eli Lilly and Company5
Jaeb Center for Health Research5
AstraZeneca4
Diasome Pharmaceuticals4
Legacy Health System4
Mannkind Corporation4
Novo Nordisk A/S4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 1178
Diabetes Mellitus34
Diabetes Mellitus, Type 216
Insulin Resistance13
Hypoglycemia12
Diabetic Nephropathies5
Diabetic Neuropathies4
Autoimmune Diseases3
Obesity3
Renal Insufficiency, Chronic3

Trials

Showing 1 to 25 of 178. Each trial links to its page on Pharma Observatory.

78 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.